Strontium citrate and hair loss is a concern raised by some individuals taking this over-the-counter bone health supplement. Strontium citrate is widely available in the UK as a food supplement, primarily marketed to support bone density, but questions have emerged about whether it may contribute to hair shedding or texture changes. This article examines the current evidence — or lack thereof — linking strontium citrate to hair loss, explores other common causes of hair changes, outlines when to seek professional advice, and highlights MHRA-recognised treatments for hair loss available in the UK.

What Is Strontium Citrate and How Is It Used?

Strontium citrate is an over-the-counter food supplement regulated by the FSA, not the MHRA, and is primarily marketed for bone density support — though clinical evidence for its efficacy is considerably more limited than for licensed strontium ranelate.

Strontium citrate is a dietary supplement containing strontium, a naturally occurring mineral that belongs to the same chemical group as calcium. It is available over the counter in the UK and is most commonly marketed to support bone density and skeletal health, particularly among postmenopausal women or individuals concerned about osteoporosis. Unlike the prescription medicine strontium ranelate (previously marketed as Protelos), strontium citrate is not licensed as a medicinal product. As a food supplement, it is regulated under UK food law by the Food Standards Agency (FSA) and enforced by local authority Trading Standards, rather than by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA would only become involved if a product made medicinal claims or was otherwise considered to function as a medicine under its borderline products guidance.

The proposed mechanism by which strontium may benefit bone health relates to its structural similarity to calcium. Strontium ions can be incorporated into the hydroxyapatite matrix of bone, and research conducted on strontium ranelate — the licensed medicine — suggests it may simultaneously stimulate osteoblast activity (bone formation) whilst inhibiting osteoclast activity (bone resorption). It is important to note that these effects are established for strontium ranelate specifically; the evidence for strontium citrate is considerably more limited, and extrapolating from one form to the other is not scientifically validated. NICE does not currently recommend strontium citrate for any clinical indication.

Two additional cautions are worth noting. First, strontium is incorporated into bone mineral and can artificially inflate bone mineral density (BMD) readings on DXA scans, potentially leading to overestimation of bone strength. Second, strontium can chelate with certain antibiotics — particularly tetracyclines and quinolones — reducing their absorption; strontium citrate should therefore be taken well apart from these medicines, and separated from calcium supplements and antacids. Anyone considering taking strontium citrate, particularly those with existing health conditions or who are taking prescribed medications, should consult a GP or pharmacist beforehand.

Evidence Behind Strontium Supplements and Hair Changes

No robust clinical trials have established a causal link between strontium citrate and hair loss; anecdotal reports exist, but alopecia data from strontium ranelate's SmPC cannot be directly applied to the supplement form.

There is currently no robust clinical evidence establishing a direct causal link between strontium citrate supplementation and hair loss. No large-scale randomised controlled trials or systematic reviews have specifically examined strontium citrate's effect on hair growth or hair shedding in humans. Because strontium citrate is a food supplement rather than a licensed medicine, it does not have MHRA or EMA adverse event listings in the way that licensed medicines do; the absence of such listings therefore reflects its regulatory status rather than confirmed safety.

Some individuals taking strontium-containing supplements have anecdotally reported changes in hair texture or increased shedding. These reports are largely confined to online forums and have not been validated through peer-reviewed research. It is worth noting that the former prescription medicine strontium ranelate had alopecia listed as an adverse reaction in its Summary of Product Characteristics (SmPC), as documented in EMA records prior to its withdrawal from most markets due to cardiovascular safety concerns. However, this does not establish that strontium citrate at typical supplement doses carries the same risk; the two forms differ in their pharmacology, dosing, and regulatory context.

Mineral imbalances more broadly are known to influence hair health. For example, high calcium intake may, in certain contexts, affect the absorption of zinc and iron — both of which are important for healthy hair follicle function — though the clinical significance of this at typical dietary or supplemental intakes is uncertain and dose-dependent. Strontium's structural similarity to calcium raises theoretical questions about whether high-dose supplementation could disrupt mineral homeostasis, but this has not been demonstrated clinically for strontium citrate at the doses found in commercially available supplements.

In the absence of definitive evidence, individuals who notice hair changes after starting strontium citrate should not automatically assume causation, but should discuss their symptoms with a healthcare professional to rule out other underlying causes.

Other Factors That May Contribute to Hair Loss

Hair loss is multifactorial; common causes include thyroid dysfunction, iron deficiency anaemia, androgenetic alopecia, and telogen effluvium, all of which should be excluded before attributing shedding to a supplement.

Hair loss is a multifactorial condition, and in most cases a single supplement is unlikely to be the sole cause. Before attributing hair changes to strontium citrate, it is important to consider the wide range of medical, nutritional, and lifestyle factors that commonly contribute to hair shedding or thinning.

Common medical causes of hair loss include:

• Thyroid dysfunction — both hypothyroidism and hyperthyroidism can cause diffuse hair thinning

• Iron deficiency anaemia — one of the most frequently identified nutritional causes of hair loss in women

• Androgenetic alopecia — the most common form of hair loss in both men and women, driven by genetic and hormonal factors

• Telogen effluvium — a temporary, stress-related shedding often triggered by illness, surgery, significant weight loss, emotional stress, or the postpartum period

• Polycystic ovary syndrome (PCOS) and female hyperandrogenism — hormonal imbalances that can contribute to hair thinning in women

• Autoimmune conditions such as alopecia areata

• Traction alopecia — caused by prolonged tension on the hair shaft from certain hairstyles

• Tinea capitis — a fungal scalp infection, particularly relevant in children, which can cause patchy hair loss with scaling

Nutritional deficiencies that may contribute include low levels of zinc, biotin, vitamin D, vitamin B12, folate, and protein. Paradoxically, excessive intake of certain supplements — including selenium and vitamin A — has been associated with hair loss, underscoring the importance of balanced nutrition over high-dose supplementation.

Certain prescribed medications are also well-documented causes of drug-induced alopecia, including anticoagulants, retinoids, and some antidepressants. If hair loss has coincided with starting any new supplement or medication, this timeline should be discussed with a GP.

A thorough history and targeted blood tests are usually the first step in identifying a reversible underlying cause. Investigations may include a full blood count, ferritin, thyroid function tests, vitamin D, vitamin B12, folate, and — where clinically indicated — inflammatory markers (CRP/ESR), coeliac serology, or serum androgens in women with features of hyperandrogenism. In many cases, addressing the root cause leads to natural hair regrowth over several months. The British Association of Dermatologists (BAD) and NHS provide condition-specific patient information on androgenetic alopecia, alopecia areata, and telogen effluvium.

When to Speak to a GP or Pharmacist

Seek GP advice promptly if hair loss is sudden, patchy, accompanied by systemic symptoms, or occurs in a child with scalp scaling, as these features may indicate conditions requiring investigation or specialist referral.

Most people experiencing mild, gradual hair thinning do not require urgent medical attention, but there are circumstances in which it is important to seek professional advice promptly. If you have recently started taking strontium citrate or any new supplement and have noticed a change in your hair — whether increased shedding, changes in texture, or visible thinning — it is reasonable to raise this with your GP or community pharmacist.

You should contact your GP if you notice any of the following:

• Sudden or rapid hair loss, particularly in patches

• Hair loss accompanied by fatigue, unexplained weight changes, or skin changes (which may suggest a thyroid or autoimmune condition)

• Scalp inflammation, redness, scaling, pustules, or scarring

• Hair loss in a child, particularly with scaly or inflamed patches (which may suggest tinea capitis and warrants prompt assessment)

• Hair loss following a recent illness, surgery, or significant life stressor

• Rapidly progressive diffuse shedding accompanied by systemic symptoms

• Concerns about a possible interaction between strontium citrate and prescribed medications

Scarring alopecia and suspected tinea capitis in children are examples of conditions that may require prompt referral to a dermatologist. A GP can arrange relevant investigations and refer appropriately where needed. A pharmacist can also provide useful guidance on whether a supplement is appropriate for you and whether it may interact with any medicines you are currently taking — including the important point that strontium should be taken well apart from tetracycline or quinolone antibiotics, and separated from calcium supplements or antacids.

Reporting concerns about supplements and medicines: If you suspect that a licensed medicine, vaccine, medical device, or herbal or homeopathic medicine has caused an adverse reaction, you can report this through the MHRA's Yellow Card scheme (yellowcard.mhra.gov.uk). For adverse reactions to food supplements such as strontium citrate, the Yellow Card scheme does not formally apply; instead, you should inform your GP, contact the retailer or manufacturer directly, and report your concern to your local Trading Standards office via the Citizens Advice consumer helpline (0808 223 1133). These routes help regulators and enforcement bodies monitor the safety of products available to consumers in the UK.

Safer Alternatives and MHRA-Recognised Treatments for Hair Loss

MHRA-licensed options for hair loss include topical minoxidil (OTC) and finasteride (prescription-only for men); for bone health, NICE supports bisphosphonates such as alendronic acid as evidence-based first-line treatment over unlicensed supplements.

For individuals experiencing hair loss, there are several evidence-based treatments available in the UK that are either licensed by the MHRA or recommended within NHS and NICE guidance. The most appropriate option will depend on the underlying cause and type of hair loss.

Licensed treatments for hair loss in the UK include:

• Topical minoxidil — available over the counter as a solution or foam, topical minoxidil is licensed for androgenetic alopecia in both men and women. It works by prolonging the anagen (growth) phase of the hair cycle and improving follicular blood supply.

• Oral minoxidil — it is important to note that oral minoxidil is licensed in the UK for hypertension, not for hair loss. Its use for hair loss is therefore off-label and should only be considered under specialist supervision following a careful risk–benefit discussion.

• Finasteride — a prescription-only oral medication licensed for male pattern baldness. It works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), the androgen primarily responsible for follicular miniaturisation. Key cautions include: it is contraindicated in women who are or may become pregnant (women should not handle crushed or broken tablets); patients should be counselled about potential sexual side effects (including reduced libido and ejaculatory dysfunction) and, rarely, mood changes; and continued use is required to maintain benefit, as hair loss typically resumes on stopping treatment.

• Corticosteroids — used topically, by intralesional injection, or occasionally systemically for inflammatory or autoimmune causes of hair loss such as alopecia areata. These treatments are clinician-directed and, for intralesional or systemic use, are typically administered under specialist (dermatology) supervision.

For hair loss related to nutritional deficiencies, correcting the underlying deficiency — through dietary changes or targeted supplementation under medical supervision — is the most effective approach. There is no strong evidence that broad-spectrum hair supplement products marketed over the counter provide meaningful benefit in the absence of a confirmed deficiency.

If you are currently taking strontium citrate primarily for bone health, it is worth discussing evidence-based alternatives with your GP. NICE guidance on osteoporosis (including NICE TA464 on bisphosphonates) supports the use of bisphosphonates such as alendronic acid as first-line pharmacological treatment, alongside adequate calcium and vitamin D intake from diet and, where necessary, licensed supplements. Where bisphosphonates are unsuitable, alternatives such as denosumab may be considered under specialist guidance. These options have a well-established safety and efficacy profile that strontium citrate, as an unlicensed supplement, cannot currently match.

Frequently Asked Questions